Clarient Licenses Biomarker for Cancer Dx, Theranostics | GenomeWeb

NEW YORK (GenomeWeb News) – Clarient today said that it has licensed from Minerva Biotechnologies exclusive rights to develop and commercialize a test that identifies the MUC1* protein, a biomarker that researchers believe may be associated with the spread of several cancers.

Clarient believes the biomarker could be used for diagnosis, therapy selection, and monitoring of drug effectiveness in solid tumors. Aliso Viejo, Calif.-based Clarient expects a further year of development to thoroughly evaluate the predictive value of measuring MUC1* in a patient's sample.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.